Pharmaceutical companies have been cautioned about a potential policy change under the Trump Administration that could tie U.S. drug prices to those of other developed countries. This emerging policy, which has become a primary concern for the industry, may be implemented by the agency managing Medicare and Medicaid programs, according to insider sources.
The contemplated move aims to address the significant discrepancies in drug prices between the United States and other nations, potentially resulting in reduced medicine costs stateside. This strategy, if adopted, could significantly impact the pricing strategies and revenue models of drugmakers in the U.S. market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for AstraZeneca PLC (AZN, Financial) is $100.29 with a high estimate of $230.38 and a low estimate of $67.00. The average target implies an upside of 48.45% from the current price of $67.56. More detailed estimate data can be found on the AstraZeneca PLC (AZN) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, AstraZeneca PLC's (AZN, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for AstraZeneca PLC (AZN, Financial) in one year is $87.34, suggesting a upside of 29.28% from the current price of $67.56. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the AstraZeneca PLC (AZN) Summary page.
